Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

New York sues OxyContin maker Purdue Pharma over opioids

Published 08/14/2018, 01:37 PM
Updated 08/14/2018, 01:37 PM
© Reuters. FILE PHOTO: Bottles of prescription painkiller OxyContin made by Purdue Pharma LP sit on a shelf at a local pharmacy in Provo

By Jonathan Stempel

NEW YORK (Reuters) - New York state on Tuesday sued Purdue Pharma LP, accusing the OxyContin maker of widespread fraud and deception in the marketing of opioids, and contributing to a nationwide epidemic that has killed thousands.

The state blamed Purdue for running what it called a reckless, decades-long scheme to mislead doctors and patients by overstating the ability of opioids to improve bodily function, while downplaying the risk of addiction.

This enabled privately held Purdue to boost prescriptions and profits, at the cost of lost lives and "devastation" in communities now "awash" with the painkillers, according to the complaint filed in the state supreme court in Suffolk County.

"The opioid epidemic was manufactured by unscrupulous distributors who developed a $400 billion industry pumping human misery into our communities," Governor Andrew Cuomo said in a statement.

"This lawsuit sends a clear message (to those) who mislead the public to increase their profit margins that we will hold you accountable," he added.

In a statement, Purdue denied New York's allegations but said it shared the state's concerns about the "opioid crisis."

The Stamford, Connecticut-based company said the U.S. Food and Drug Administration "continues to approve" of scientific and medical information it has provided to doctors.

New York is seeking to impose civil fines, recoup profits and obtain other damages, including for creating an alleged "criminal nuisance."

Purdue sold $1.74 billion of OxyContin in 2017, according to Symphony Health Solutions.

Opioid makers and distributors face hundreds of lawsuits by U.S. states, counties and cities accusing them of using deceptive marketing to sell the painkillers.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

New York joined at least 26 other U.S. states and Puerto Rico to sue Purdue over opioids.

Connecticut is not among those states but has been part of a 41-state coalition investigating the opioid industry. Some of its larger cities, including Bridgeport, New Haven and Waterbury, have sued Purdue.

In January, New York City filed its own lawsuit seeking $500 million from Purdue and seven other opioid makers and distributors to fight the opioid crisis there.

Opioids, including prescription painkillers and heroin, played a role in a record 42,249 U.S. deaths in 2016, according to the U.S. Centers for Disease Control and Prevention.

This included at least 3,086 deaths in New York state and more than 1,100 in New York City.

In 2007, Purdue and three executives pleaded guilty to misbranding OxyContin and agreed to pay $634.5 million to resolve a U.S. Department of Justice investigation.

The case is New York v Purdue Pharma LP et al, New York State Supreme Court, Suffolk County, No. 400016/2018.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.